You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Revenues were $4.49 billion, up from $2.95 billion in the same quarter last year and beating analysts' average estimate of $3.95 billion.
The firm's life science revenues increased nearly fivefold, while diagnostics revenues declined 13 percent year over year.
The firm's Discovery and Analytical Solutions business revenues grew 1 percent year over year, while its Diagnostics revenues more than doubled.
Of the 32 companies in the index, 27 firms saw their stock prices increase, while 5 saw their share prices decline.
Exact Sciences discussed newly released data and its plans for Cologuard, while Luminex provided details about its warning letter from the FDA.
The company also projected full year 2020 revenue of between $84 million and 86 million and said that its instrument install base grew 34 percent over the year.
Despite the Q4 revenue increase, sales for FY2020 dropped 13 percent year over year to $5.2 million.
During the quarter, the Tucson, Arizona-based company added 45 instruments for a total of 268 revenue-generating instruments installed in the US.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
The firm said the increase in revenues was partly driven by a 9 percent increase in screening revenues.
